NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis → Americans Now Need $1.46M to Retire… (From Crypto 101 Media) (Ad) Free DCTH Stock Alerts $6.96 -0.23 (-3.20%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$6.89▼$7.4050-Day Range$3.72▼$7.1952-Week Range$2.25▼$7.99Volume306,901 shsAverage Volume240,714 shsMarket Capitalization$193.38 millionP/E RatioN/ADividend YieldN/APrice Target$20.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Delcath Systems alerts: Email Address Delcath Systems MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside190.2% Upside$20.20 Price TargetShort InterestBearish3.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 19 Articles This WeekInsider TradingAcquiring Shares$100,001 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.45) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.09 out of 5 starsMedical Sector368th out of 929 stocksSurgical & Medical Instruments Industry54th out of 99 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDelcath Systems has only been the subject of 2 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.34% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Delcath Systems has recently increased by 13.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 3.1 News and Social Media Coverage News SentimentDelcath Systems has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Delcath Systems this week, compared to 2 articles on an average week.Search Interest12 people have searched for DCTH on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.MarketBeat Follows6 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,001.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.94% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($1.45) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 9.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Delcath Systems' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Delcath Systems Stock (NASDAQ:DCTH)Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More DCTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCTH Stock News HeadlinesMay 17 at 2:14 AM | americanbankingnews.comDelcath Systems, Inc. (NASDAQ:DCTH) Receives $18.50 Average Price Target from AnalystsMay 16 at 4:28 AM | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Coverage Initiated at StephensMay 16 at 12:22 AM | markets.businessinsider.comDelcath Systems: Strong Financials and HEPZATO KIT Growth Prompt Buy Rating and Raised Price TargetMay 15 at 6:18 AM | americanbankingnews.comDelcath Systems, Inc. (NASDAQ:DCTH) Sees Significant Increase in Short InterestMay 15 at 3:52 AM | finance.yahoo.comDelcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 15 at 1:27 AM | msn.comStephens & Co. Initiates Coverage of Delcath Systems (DCTH) with Overweight RecommendationMay 14 at 9:59 AM | markets.businessinsider.comDelcath Systems Inc. Q1 Loss Beats EstimatesMay 14 at 7:30 AM | prnewswire.comDelcath Systems Reports First Quarter 2024 Results and Business HighlightsMay 13, 2024 | markets.businessinsider.comDelcath Systems Poised for Commercial Success with HEPZATO-KIT Launch, Analyst Issues Buy RatingMay 12, 2024 | americanbankingnews.comDelcath Systems (DCTH) to Release Earnings on TuesdayMay 7, 2024 | prnewswire.comDelcath Systems to Host First Quarter 2024 Earnings CallMay 6, 2024 | prnewswire.comPublication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KITMay 3, 2024 | prnewswire.comDelcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | finance.yahoo.comDelcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)March 27, 2024 | finance.yahoo.comDelcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | finance.yahoo.comDelcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic AdvancementsMarch 26, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 26, 2024 | msn.comDelcath Systems GAAP EPS of -$0.48, revenue of $0.54MMarch 26, 2024 | prnewswire.comDelcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 25, 2024 | msn.comDelcath Systems Q4 2023 Earnings PreviewMarch 23, 2024 | finance.yahoo.comInsiders of Delcath Systems Getting Good Value On Their US$736.5k InvestmentMarch 20, 2024 | prnewswire.comDelcath Systems Closes $7 Million Private PlacementMarch 19, 2024 | prnewswire.comDelcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update CallSee More Headlines Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/16/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees76Year FoundedN/APrice Target and Rating Average Stock Price Target$20.20 High Stock Price Target$25.00 Low Stock Price Target$13.00 Potential Upside/Downside+190.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,680,000.00 Net Margins-2,308.86% Pretax Margin-2,308.86% Return on Equity-563.60% Return on Assets-111.13% Debt Debt-to-Equity RatioN/A Current Ratio2.26 Quick Ratio2.06 Sales & Book Value Annual Sales$2.07 million Price / Sales93.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book9.67Miscellaneous Outstanding Shares27,784,000Free Float22,800,000Market Cap$193.38 million OptionableOptionable Beta0.55 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Gerard J. Michel MBA (Age 61)MS, CEO & Director Comp: $727.97kMs. Sandra Pennell (Age 44)Senior VP of Finance and Principal Financial & Accounting Officer Dr. Martha S. Rook Ph.D. (Age 54)Chief Operating Officer Mr. David HoffmanGeneral Counsel, Corporate Secretary & Chief Compliance OfficerDr. Johnny John M.D. (Age 59)Senior Vice President of Clinical Operations & Medical Affairs Comp: $472.16kDr. Vojislav Vukovic M.D. (Age 57)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsProfound MedicalNASDAQ:PROFOrchestra BioMedNASDAQ:OBIOAlpha Tau MedicalNASDAQ:DRTSQuipt Home MedicalNASDAQ:QIPTAVITA MedicalNASDAQ:RCELView All CompetitorsInsiders & InstitutionsBVF Inc. ILBought 225,918 shares on 5/16/2024Ownership: 4.327%Levin Capital Strategies L.P.Bought 5,969 shares on 5/16/2024Ownership: 0.198%Vanguard Group Inc.Bought 161,678 shares on 5/10/2024Ownership: 2.461%Vivo Capital LLCBought 811,555 shares on 4/22/2024Ownership: 6.552%Gil AharonBought 26,882 shares on 3/19/2024Total: $100,001.04 ($3.72/share)View All Insider TransactionsView All Institutional Transactions DCTH Stock Analysis - Frequently Asked Questions Should I buy or sell Delcath Systems stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks. What is Delcath Systems' stock price target for 2024? 5 Wall Street research analysts have issued 1 year target prices for Delcath Systems' stock. Their DCTH share price targets range from $13.00 to $25.00. On average, they predict the company's stock price to reach $20.20 in the next twelve months. This suggests a possible upside of 190.2% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts. How have DCTH shares performed in 2024? Delcath Systems' stock was trading at $4.16 at the beginning of the year. Since then, DCTH shares have increased by 67.3% and is now trading at $6.96. View the best growth stocks for 2024 here. When is Delcath Systems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our DCTH earnings forecast. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) issued its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.19. The business had revenue of $0.54 million for the quarter, compared to analysts' expectations of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative trailing twelve-month return on equity of 563.60%. During the same period in the prior year, the company posted ($0.86) EPS. When did Delcath Systems' stock split? Delcath Systems's stock reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Delcath Systems' major shareholders? Delcath Systems' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (6.55%), BVF Inc. IL (4.33%), Vanguard Group Inc. (2.46%), Levin Capital Strategies L.P. (0.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ernest C Garcia II, Gerard J Michel, Gil Aharon, John Purpura, John Richard Sylvester, Rosalind Advisors, Inc, Sandra Pennell, Steven A J Salamon and Vojo Vukovic. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCTH) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
